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Abstract
Background: The use of an implantable cardioverter defibrillator (ICD) is a widely used and effective therapy, which
reduces the risk of cardiac death in many cardiac diseases, both implanted for secondary and primary prevention.
However, recurrent arrhythmias and ICD discharges have adverse prognostic significance. Additional parameters
that would identify patients who are at increased risk of arrhythmias and appropriate ICD interventions would be of
clinical value. Modern ICDs are relatively complex devices with a number of functions, including the possibility to
perform noninvasive programmed stimulation (NIPS) with an implanted electrode located in the right ventricle.
Methods/Design: The aim of the study is to evaluate the usefulness of NIPS in determining the likelihood of life-
threatening arrhythmic events in patients with ICD. The study will include 150 consecutive patients with an ICD
implanted both for primary and secondary prevention, regardless of etiology, who are followed in the outpatient
clinic of our center and do not meet the exclusion criteria. A 12-step St. George’s Hospital NIPS protocol using ICD
will be performed. The endpoint is to induce sustained ventricular arrhythmia (VT lasting more than 30 seconds or
hemodynamically unstable VT/VF) or the end of the protocol. In case of serious and/or hemodynamically unstable
heart rhythm disorders resistant to treatment with a low-energy antiarrhythmic pacing (ATP), the patient receives a
short-term intravenous general anesthesia, and internal or external defibrillation is performed. Outpatient follow-up
will be conducted during the pre-scheduled ICD control visits. An analysis of records of a registered memory device
will be collected, a patient will be interviewed, and physical examination will be carried out. The follow-ups will be
held every 3 months for 1 year. The primary endpoint of the follow-up will be appropriate intervention of ICD or
sudden cardiac (arrhythmic) death; the secondary, appropriate ICD intervention, or death from cardiovascular
causes; and the tertiary, appropriate ICD intervention, death or hospitalization for cardiovascular causes.
Discussion: It is expected that appropriate ICD interventions during follow-up will occur more often in patients
who had sustained ventricular arrhythmias induced during NIPS.
Clinical trials registry: ClinicalTrials.gov, NCT02373306, date of registration: 26 February 2015.
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Background
Implantable cardioverter defibrillator (ICD) is a widely
used and effective therapy that reduces the risk of car-
diac death in many cardiac diseases, and is implanted for
secondary and primary prevention [1–9]. In the case of
new-onset or recurrence of life-threatening ventricular
arrhythmia, the device interrupts it by anti-arrhythmic
pacing (ATP) or by electrical shock. It is known that re-
current arrhythmias and ICD discharges have adverse
prognostic significance. ICD therapeutic interventions
are often associated with the sensation of pain, reduce
the device’s battery life, are associated with the risk of
serious proarrhythmia, and can shorten the patient’s life
[10–13]. Moreover, in the case of hemodynamically un-
stable arrhythmia, the late arrival of the device’s inter-
vention may not protect patients from syncope and their
consequences [14].
In view of the above-mentioned aspects, additional pa-
rameters that would identify patients who are at in-
creased risk of arrhythmias and appropriate ICD
interventions would be of clinical value. Some studies
have shown that factors predicting ventricular tachycar-
dia (VT) or ventricular fibrillation (VF) recurrences, and
consequently ICD interventions, include the patient’s
age, NYHA class heart failure, left ventricular ejection
fraction (LVEF), the presence of atrial fibrillation (AF),
the QRS complex width, and the status of renal function
[15, 16]. However, the accuracy of these parameters is
limited, and other variables that may identify vulnerable
patients are sought. This may have important clinical im-
plications because such patients could receive more
aggressive antiarrhythmic therapy or may undergo
prophylactic ablation of arrhythmia substrate to prevent
the occurrence of arrhythmias and ICD discharges. In-
deed, some studies have suggested that it might be worth-
while to perform prophylactic ablation of VT in patients
with previously implanted ICD [17, 18]; however, this ap-
proach has not entered into daily clinical practice [19].
One of the methods of risk stratification for sudden
cardiac death that has been used for many years is pro-
grammed ventricular stimulation (PVS) [20, 21]. This is
an invasive study assessing the likelihood of VT or VF
induced by stimulation to occur. This test also has been
used in order to qualify for prophylactic ICD implant-
ation in patients with LVEF 31 to 40 % and nonsustained
VT in ambulatory ECG [1, 9]. The primary disadvantage
of PVS is its invasiveness. Modern ICDs are relatively
complex devices with a number of functions, including
the possibility to perform non-invasive programmed
stimulation (NIPS) with an implanted electrode located
in the right ventricle. NIPS is readily available, inexpen-
sive, minimally burdening the ICD battery, and less dis-
turbing to the patient, because it does not require any
invasive procedure [22–24].
Some studies suggested that appropriate interven-
tions occur more frequently in patients who had ven-
tricular arrhythmias induced by NIPS, but the
prognostic significance of NIPS has not yet been de-
termined [22, 25, 26]. One of the first NIPS-related
studies demonstrated that VF/VT inducibility during
the test of the device can help to optimize the ICD
programming; however, the predictive value of NIPS
had not been studied at that time [22]. In another
study, one of the first and few on the prognostic
value of NIPS, it has been shown that induction of
monomorphic, especially relatively slow VT (cycle
length > 280 ms) was prognostic for recurrence of ar-
rhythmias [25]. This study was relatively small, the
distribution of the etiology had not been considered,
and some of the results were surprising; for example,
previous myocardial infarction of inferior wall, rather
than the anterior wall, predicted altered outcome,
whereas the LVEF had no prognostic value. In
addition, these studies were conducted many years ago,
when the use of primary angioplasty for acute myocardial
infarction was low, and therefore the clinical characteris-
tics of the patient groups from that period are different
than those of contemporary patients.
Methods/Design
The study protocol was approved by the Ethics Commit-
tee of Regional Medical Chamber in Rzeszów and is in
full compliance with the Declaration of Helsinki. Ap-
proval Number: 77/2013/B.
The aim of the study
The aim of the study is to evaluate the usefulness of
NIPS in determining the likelihood of life-threatening
arrhythmic events in patients with ICD.
Methodology/Design
The study group
The study will include 150 consecutive patients with an
ICD implanted both for primary and secondary preven-
tion, regardless of etiology, who are followed in the out-
patient clinic of our center and do not meet the
following exclusion criteria:
1. lack of consent for NIPS
2. decompensated heart failure
3. unstable angina
4. persistent/long standing AF without effective
anticoagulation (risk of sinus rhythm return during
NIPS)
5. thrombus in the left ventricle
6. appropriate device interventions during the 40 days
prior to planned NIPS
7. pacing/sensing problems
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After selecting a patient to undergo NIPS, the follow-
ing parameters will be analyzed: etiology, age, sex, and
anthropometric measurements (weight, height, and
waist), echocardiogram performed within 3 months after
enrollment (including LVEF and end-diastolic dimension
of LV), NYHA class, presence of AF, state of renal func-
tion, width of native and paced QRS complex, occur-
rence of ventricular arrhythmias (detected on ECG or
EGM), previously performed cardiac surgery and/or cor-
onary angioplasty, occurrence of ICD interventions in
the past, and current drug therapy.
NIPS methodology
On admission, the patient will be fasting. After inter-
viewing and physical examination, the patient will be in-
formed about the manner and purpose of the NIPS, and
written consent will be obtained. The ECG will be re-
corded, and access to the venous system will be ob-
tained. The patient will be transferred to the EP room.
Throughout the duration of the NIPS, surface 12-lead
ECG from an electrophysiological system will be re-
corded. ICD will be interrogated, and a review of the
available events and interventions in memory ICD will
be performed. The parameters of the detection of VT/
VF and therapy parameters will be set out, as well as the
parameters of stimulation and sensing: the low and high
voltage impedance, the signal from the defibrillation
lead, and the pacing threshold.
Next, a 12-step St. George’s Hospital NIPS protocol
using ICD will be performed [27, 28], which consists of
introduction of a single and double extrastimuli from
the pacing lead during sinus rhythm (or atrial fibrillation
if present) and after eight-beat extrastimulus drive trains
at paced cycle lengths of 600, 500, and 400 ms. If a sus-
tained arrhythmia will not be inducible, the procedure
will be repeated using triple extrastimuli, wherein in step
12 the three premature impulses after the eight-beat
drive at cycle length of 400 ms are delivered.
The endpoint is to induce sustained ventricular
arrhythmia (VT lasting more than 30 seconds or
hemodynamically unstable VT/VF) or the end of the
protocol. In case of ventricular arrhythmias induction,
the following parameters will be defined:
1. arrhythmia-induction protocol (stage of NIPS at
which arrhythmia was induced)
2. the type of arrhythmia (single extrasystoles, couplets,
nonsustained VT (nsVT), sustained VT (sVT), or VF)
3. In the case of VT/VF occurrence:
a. mean tachycardia cycle length calculated from the
first 10 QRS complexes
b. effectiveness of ATP in terminating arrhythmia
c. in the case of ineffectiveness of ATP - efficacy of
internal cardioversion/defibrillation.
In case of serious and/or hemodynamically unstable
heart rhythm disorders resistant to treatment with a
low-energy ATP, the patient receives a short-term intra-
venous general anesthesia, and internal or external de-
fibrillation is performed.
If the test induces sustained ventricular arrhythmia,
after the sinus rhythm has been restored, the patient will
be transferred to the intensive care room, where at the
time of his stay, continuous ECG and blood pressure will
be performed.
Outpatient follow-up
The follow-up will be conducted at the outpatient clinic
for patients with ICD located in our center. Analysis of
records of registered memory device classified as VT/VF
episodes will be collected in printed and electronic ver-
sions for further investigation by the study team. Med-
ical history will be taken, and a physical examination will
be carried out. In case of endpoint VT/VF occurrence
during follow-up, the time from NIPS test to ICD epi-
sode detection/therapy will be measured. The follow-up
will last one year and will be conducted every 3 months;
thus, each patient will have four visits – one at 3, 6, 9
and 12 months after performing NIPS. The following pa-
rameters will be collected:
1. The patient’s clinical status will be determined on
the basis of a physical examination, NYHA class,
changes in medication, hospitalizations, cardiac
events such as syncope, ICD discharges, palpitations
and other, which occurred after the previous visit.
2. The ICD memory will be examined, and all events
will be analyzed. All ICD interventions will be
analyzed and classified as appropriate or
inappropriate. The type of cardiac rhythm (VF, VT,
or other) and the cycle length and duration will be
also measured.
3. All follow-up visits and data collection will be per-
formed by the principal investigator (PF). If neces-
sary, drug therapy will be modified during follow-up,
but the result of the NIPS will not be taken into ac-
count when changes in the antiarrhythmic drug
therapy are considered. Changes in ICD program-
ming will be possible; however, these will be based
on arrhythmic events occurring during follow-up
and not based on the results of the NIPS.
Expected results
During the NIPS the following clinical situations are ex-
pected to occur:
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1. lack of induction of arrhythmia (negative result)
2. induction of ventricular extrasystoles (negative
result)
3. induction of hemodynamically stable nsVT (negative
result)
4. induction of hemodynamically unstable nsVT
(positive result)
5. sVT induction (positive result)
6. VF induction (positive result).
It is expected that appropriate ICD interventions dur-
ing follow-up will occur more often in patients who had
sustained ventricular arrhythmias induced during NIPS
(positive result). The primary endpoint of the follow-up
will be appropriate intervention of ICD or sudden car-
diac (arrhythmic) death; the secondary, appropriate ICD
intervention or death from cardiovascular causes; and
the tertiary, appropriate ICD intervention, death or
hospitalization for cardiovascular causes. Because all pa-
tients will remain under the study follow-up for 1 year,
the degree of exposure to arrhythmia recurrence
(arrhythmia burden) will be determined defined as the
number of relevant interventions during the year of
observation.
Appropriate ICD intervention is defined as the high or
low energy treatment due to the occurrence and detec-
tion of VT/VF.
For death from cardiovascular causes, it is considered
death due to VF, extensive myocardial infarction, end-
stage heart failure, or electromechanical dissociation or
asystole due to presumed cardiovascular cause.
For sudden cardiac (arrhythmic) death, death due to
sVT/VF or, in the absence of available documentation,
death that occurred within 1 hour of the onset of symp-
toms [29] may be considered. Every effort will be made
to interrogate ICD postmortem in order to establish the
mode of death.
Statistical methods
The principal analysis will examine the relationship be-
tween positive NIPS result and the follow-up outcome.
Further subanalyses will also take into account the
protocol stage at which arrhythmia was induced as well
as the tachycardia cycle length and duration. At the first
stage, groups of patients will be extracted by the occur-
rence of arrhythmic events during NIPS,- as in section
4. Afterwards, these groups will be compared according
to the data collected during the follow-up (endpoints).
The group, in which the endpoints occurred, will be
compared with a group of patients without endpoints
according to the NIPS result using Kaplan–Meier sur-
vival curves and tested with a log-rank test. A P value
of 0.05 will be considered statistically significant for
all analyses.
Next, with Multivariate Cox Proportional Hazards
Model the presence or absence of the NIPS result
correlation will be determined with other risk factors
affecting the possibility of developing adequate ICD
interventions that have been previously described in
the available literature and widely accepted, that is,
echocardiogram result, NYHA class, the presence of
atrial fibrillation, renal function, width of native QRS
complexes. The sensitivity, specificity, positive, and
negative predictive value in predicting the occurrence
of NIPS endpoints also will be calculated using Stu-
dent’s t test or the Mann–Whitney test for continu-
ous variables, where appropriate.
With the chi-square test, 150 patients have been esti-
mated as needed for inclusion in the study. This as-
sumption is based on the calculation that primary
endpoints will occur in 6.7 % patients, and the result of
NIPS will be abnormal in 30 % of those patients and in
7.9 % of patients without VT/VF recurrences [2, 30, 31].
This number of patients will be sufficient to demonstrate
significant difference (P < 0.05) between the groups.
Discussion
This study will provide information regarding the result
of NIPS on the occurrence of life-threatening arrhythmic
events in patients with ICD. It is expected that appropri-
ate ICD interventions during follow-up will occur more
often in patients who had sustained ventricular arrhyth-
mias induced during NIPS. Consequently, these patients
may require more aggressive antiarrhythmic therapy or
prophylactic ablation of arrhythmia substrate to prevent
the occurrence of arrhythmias and ICD discharges.
Limitations
The study has some limitations. First, although all con-
secutive patients attending our outpatient clinic will be
invited to the study, probably not all will give consent to
enter the trial. Thus, the study group will consist of all
consecutive patients who agreed to participate in the
study but not of all our patients with ICD. However, a
logbook including all ICD patients will be maintained,
so we will know exactly what percentage of our ICD pa-
tients entered the study. Secondly, the physician per-
forming follow-up visits will not be blinded to the
results of NIPS. However, as a rule, medication or ICD
programming will not be influenced by NIPS results
because there are no data indicating that this should
be done. It is our and similar studies which should
shed more light on this issue and answer the ques-
tion whether NIPS results can be taken into account
when medication and ICD programming changes are
concerned.
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Trial status
This study is currently recruiting participants.
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